Safety and Effectiveness of a Novel Laser-Based Intravascular Lithotripsy System for Coronary Calcium: FRACTURE Study.

JACC Cardiovasc IntervOct 26, 2026
Clinical ResearchCardiology

Margaret McEntegart, Povilas Budrys, Samin Sharma et al.

✦ AI-curated · Sources linked

In 30 seconds

FRACTURE was a prospective, multicenter, single-arm clinical trial evaluating a laser- and optic-based quad-emitter intravascular lithotripsy system in patients with severely calcified de novo coronary lesions. Among 420 enrolled patients, 30-day freedom from major adverse cardiac events was 93.3% (373/400), exceeding the prespecified 86.2% performance goal. Procedural success was 93.7% (374/399), also above its 85.8% performance goal. In the optical coherence tomography substudy, calcium fracture was confirmed in 67% of lesions. The authors concluded that the system can modify severe coronary calcium and facilitate stent implantation.

Key findings

  • Thirty-day freedom from major adverse cardiac events was 93.3% (373/400), exceeding the 86.2% performance goal (P < 0.0001).
  • Procedural success was 93.7% (374/399), exceeding the 85.8% performance goal (P < 0.0001).
  • Optical coherence tomography confirmed calcium fracture in 67% of lesions in the 106-patient substudy.

Why it matters

Severe coronary calcium can complicate stent delivery and implantation. This study provides prospective, multicenter evidence that a novel IVL system achieved high procedural success and met prespecified safety and effectiveness goals in this setting. The OCT findings also offer evidence of calcium modification, although the trial design does not establish comparative benefit over other approaches.

What to keep in mind

The trial was single-arm and assessed outcomes against prespecified performance goals rather than a concurrent comparator. OCT findings came from a substudy of 106 patients.

Source

Published in JACC Cardiovasc Interv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.